A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL14)

Publisher： Karger

E-ISSN： 2296-5262|39|1-2|69-71

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.39, Iss.1-2, 2016-0, pp. : 69-71

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody

By  

Oncology Research and Treatment, Vol. 38, Iss. 4, 2015-03 ,pp. : 185-192

Karger

Access to resources Recommend Favorite

Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 327-333

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ofatumumab‐based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3788-3796

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia‐associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS)

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 3, 2015-03 ,pp. : 204-207

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of chronic lymphocytic leukemia (CLL) in the era of B‐cell receptor signal transduction inhibitors

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 657-664

John Wiley & Sons Inc

Access to resources Recommend Favorite